Globus Medical Inc. Class A Common Stock vs Union Pacific Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Union Pacific Corporation trades at $287 (market cap $167.74B). The key difference: Union Pacific Corporation is far larger — about 16.4× Globus Medical Inc. Class A Common Stock's market cap, and Union Pacific Corporation pays a 2.01% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Union Pacific Corporation for 105 Days on average.
| GMED | UNP | |
|---|---|---|
Market Cap | $10.25B | $167.74B |
Volume | 1,108,124 | 1,359,371 |
Sector | Health | Industrials |
52-Week High | $96.82 | $310.62 |
52-Week Low | $58.33 | $216.37 |
Typical Hold Time | 0 Days | 105 Days |
Enterprise Value | $9.76B | $196.80B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Union Pacific (UNP) trades at $286.43, up 1.73% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 28.85% net income margin and 39.7% ROE, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by analyst upgrades, a consensus buy rating, and a $332.10 price target, alongside developments in battery-electric locomotives and the pending Norfolk Southern combination.
The outlook for UNP is favorable, with earnings growth and dividend stability offering investment appeal. Risks include merger uncertainty, fuel cost pressures, and economic cyclicality, but the company's pricing power and infrastructure advantages provide a solid foundation for long-term value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →